Previous close | 2.3300 |
Open | 2.2100 |
Bid | 2.0100 |
Ask | 2.2300 |
Strike | 27.50 |
Expiry date | 2025-01-17 |
Day's range | 2.0500 - 2.2200 |
Contract range | N/A |
Volume | |
Open interest | 46.13k |
Andrew Baum, the prominent Wall Street drug company analyst will be the pharma firm’s chief strategy and innovation officer.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.